Breast Carcinoma Presenting as Immune Thrombocytopenic Purpura

Fadilah, S A W; Fun, Leong Chong; Keng, Cheong Soon; Ismail, Fuad

doi:10.1007/bf02981970

Cited by 13 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results seemed similar to ITP-like cancer patients, where high-dose Cs (50-80 mg/day) proved effective in 1-3 weeks time in 17 of 24 (70%) treated patients, completely in 12, and partially in five [1,2,4,[9][10][11][12][13][14][15][16]. However, thrombocytopenia relapsed in eight (60%) of 14 of patients on tapering Cs dose [11,12,14].…”

Section: Discussionsupporting

confidence: 66%

“…The syndrome regressed in two (66%) responders (1 CR and 1 PR) and in 1 of unknown response [8,10,[13][14][15].…”

Section: Discussionmentioning

confidence: 99%

“…Whenever ITP-like syndrome interferes with invasive procedures or chemotherapy application, even in chemosensitive carcinomas, as in our patient, its treatment precedes, and, if effective, makes further approaches safe [1,[10][11][12]14].…”

Section: Discussionmentioning

confidence: 99%

“…Clinical information on this thrombocytopenic condition is scarce and is mainly derived from case reports [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] referring to adults with carcinomas of the breast, gastrointestinal tract, lung, ovary, testis, prostate, urinary bladder, kidney, skin, and vagina.…”

Section: Introductionmentioning

confidence: 99%

“…On the other hand, bone marrow infiltration [9,10,13,14] may change the bone marrow milieu, producing an immune-mediated thrombocytopenia [9].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Successful treatment of idiopathic thrombocytopenic purpura‐like syndrome in a cancer patient with low‐dose interferon: Case report and review of the literature

et al. 2004

View full text Add to dashboard Cite

Idiopathic thrombocytopenic purpura (ITP)-like syndrome is a rare complication of carcinomas, and its treatment usually precedes cancer therapy in order to make further procedures safe. We describe the case of a 78-year-old man with a small-cell lung cancer of extended stage, associated with ITP-like syndrome, which proved resistant to treatment with corticosteroids and vincristine, short-responsive to IV immunoglobulin, but quickly and steadily responsive to low-dose interferon (ld IFN, 3 million IU, sc, twice weekly, for 8 weeks), until the patient's death, due to his primarily chemoresistant cancer. This case is, to our knowledge, the second reported ITP-like syndrome in a cancer patient who had been successfully treated with ld IFN. The excellent and cost-effective therapeutic index of ld IFN makes it an attractive alternative treatment in patients with this specific complication and calls for further investigation regarding its potential use as a first-line treatment. Am.

show abstract

Section: Discussionsupporting

confidence: 66%

“…The syndrome regressed in two (66%) responders (1 CR and 1 PR) and in 1 of unknown response [8,10,[13][14][15].…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…On the other hand, bone marrow infiltration [9,10,13,14] may change the bone marrow milieu, producing an immune-mediated thrombocytopenia [9].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Successful treatment of idiopathic thrombocytopenic purpura‐like syndrome in a cancer patient with low‐dose interferon: Case report and review of the literature

et al. 2004

View full text Add to dashboard Cite

show abstract

Naturally occurring B-cell responses to breast cancer

Coronella-Wood

Hersh

2003

Cancer Immunology, Immunotherapy

143

123

View full text Add to dashboard Cite

As demonstrated by the effectiveness of trastuzumab, antibodies against breast cancer antigens are a potentially potent mechanism of tumor control. While trastuzumab is administered exogenously, its efficacy suggests that induction of very high titer antibody responses in vivo might also be therapeutic. Both naturally occurring and vaccine-induced antibody responses to some breast cancer antigens are associated with improved survival in some cases. However, the improvement in survival associated with antibody responses to breast cancer is modest, and tumor regression is not known to be associated with the natural antitumor antibody response, indicating a need for improved understanding of the natural antitumor antibody response. Naturally occurring B-cell responses in the form of serum antibody, tumor reactive lymph node B cells, and tumor-infiltrating B cells have been described, and a variety of breast tumor-associated antigens have been identified based on reactivity of patient antibodies. This review discusses current knowledge of humoral immunity to breast cancer with regard to specific antigens and the basis for their immunogenicity, and the contexts (tumor, lymph node, serum) in which responses are observed. With few exceptions, "tumor-associated antigens" identified with naturally occurring antibodies may be overexpressed on tumor but are in fact nonspecific autoantigens. This suggests that while overexpression or aberrant processing can increase immunogenicity in some cases, the immunogenicity of many or even most tumor-associated antigens is a function of expression in tumor or the result of ancillary tumor factors.

show abstract